About this Research Topic
Many endocrine neoplasms can be subcategorized by their molecular signatures that are associated with different tumor biology. Such information can be leveraged to individualize treatment and surveillance strategies. Because many of the enriched and/or dysregulated molecular features can be targeted with newly discovered inhibitors, treatment options for the endocrine neoplasms have expanded and become more specific to patient tumor molecular profiles with less toxicity.
This Research Topic aims to review the up-to-date molecular features of various endocrine neoplasms and to highlight the clinical applicability in all aspects of patient care including molecular diagnostics, risk-stratification, current and future treatments, and surveillance plans. The articles in this Research Topic describe several key subjects in thyroid cancer such as the clinical utility of molecular diagnostics, the clinical implication of hTERT regulation, personalized approach in thyroid surgery, and an update on therapeutics in medullary and non-medullary thyroid cancer. In addition, it includes the review of molecular features of various benign and malignant adrenal neoplasms as well as current and future treatments. Several articles also discuss sporadic and familial endocrine diseases involving parathyroid glands and gastrointestinal and pancreatic neuroendocrine tumors with a focus on their molecular features and clinical applicability.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.